Elevated levels of 14-3-3 proteins, serotonin, gamma enolase and pyruvate kinase identified in clinical samples from patients diagnosed with colorectal cancer.

BACKGROUND Colorectal cancer (CRC), a heterogeneous disease that is common in both men and women, continues to be one of the predominant cancers worldwide. Lifestyle, diet, environmental factors and gene defects all contribute towards CRC development risk. Therefore, the identification of novel biomarkers to aid in the management of CRC is crucial. The aim of the present study was to identify candidate biomarkers for CRC, and to develop a better understanding of their role in tumourogenesis. METHODS In this study, both plasma and tissue samples from patients diagnosed with CRC, together with non-malignant and normal controls were examined using mass spectrometry based proteomics and metabolomics approaches. RESULTS It was established that the level of several biomolecules, including serotonin, gamma enolase, pyruvate kinase and members of the 14-3-3 family of proteins, showed statistically significant changes when comparing malignant versus non-malignant patient samples, with a distinct pattern emerging mirroring cancer cell energy production. CONCLUSION The diagnosis and management of CRC could be enhanced by the discovery and validation of new candidate biomarkers, as found in this study, aimed at facilitating early detection and/or patient stratification together with providing information on the complex behaviour of cancer cells.

[1]  Weidong Zhou,et al.  Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. , 2012, Journal of proteome research.

[2]  N Leigh Anderson,et al.  High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. , 2008, Clinical chemistry.

[3]  Akiko Sakai,et al.  Identification of phosphorylated serine-15 and -82 residues of HSPB1 in 5-fluorouracil-resistant colorectal cancer cells by proteomics. , 2012, Journal of proteomics.

[4]  M. Kaste,et al.  Neurological outcome after out-of-hospital cardiac arrest. Prediction by cerebrospinal fluid enzyme analysis. , 1989, Archives of neurology.

[5]  K. Yasumoto,et al.  A case of primary small cell carcinoma of the breast , 2007, Breast cancer.

[6]  Investigating the clinical potential for 14-3-3 zeta protein to serve as a biomarker for epithelial ovarian cancer , 2013, Journal of Ovarian Research.

[7]  Ruedi Aebersold,et al.  Protein expression changes in ovarian cancer during the transition from benign to malignant. , 2012, Journal of proteome research.

[8]  H. Kretzschmar,et al.  14-3-3 CSF levels in sporadic Creutzfeldt–Jakob disease differ across molecular subtypes , 2009, Neurobiology of Aging.

[9]  Christian Gieger,et al.  Metabolic Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological Setting , 2010, PloS one.

[10]  B. McManus,et al.  The Human Serum Metabolome , 2011, PloS one.

[11]  G. Papadopoulos,et al.  Surgical management in lung metastases from colorectal cancer. , 2007, Anticancer research.

[12]  S. Baba,et al.  14-3-3 Protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid , 2011, Analytical and bioanalytical chemistry.

[13]  Judy Yan,et al.  PKM2 contributes to cancer metabolism. , 2015, Cancer letters.

[14]  H. Wakabayashi,et al.  Increased levels of epsilon and gamma isoforms of 14-3-3 proteins in cerebrospinal fluid in patients with Creutzfeldt-Jakob disease. , 1999, Clinical and Diagnostic Laboratory Immunology.

[15]  P. Righetti,et al.  The ProteoMiner in the proteomic arena: a non-depleting tool for discovering low-abundance species. , 2008, Journal of proteomics.

[16]  J. Hill,et al.  Review of biomarkers in colorectal cancer , 2012, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[17]  H. Homburger,et al.  Quantitation of 14-3-3 and neuron-specific enolase proteins in CSF in Creutzfeldt–Jakob disease , 2001, Neurology.

[18]  C. Clarke,et al.  Impact of miR-7 over-expression on the proteome of Chinese hamster ovary cells. , 2012, Journal of biotechnology.

[19]  A. Brunet,et al.  FOXO transcription factors , 2007, Current Biology.

[20]  A. Vlahou,et al.  Secretome proteomics for discovery of cancer biomarkers. , 2010, Journal of proteomics.

[21]  Michael B Yaffe,et al.  How do 14‐3‐3 proteins work? – Gatekeeper phosphorylation and the molecular anvil hypothesis , 2002, FEBS letters.

[22]  G. Tzivion,et al.  FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. , 2011, Biochimica et biophysica acta.

[23]  Rong Zeng,et al.  Human plasma proteome analysis by multidimensional chromatography prefractionation and linear ion trap mass spectrometry identification. , 2005, Journal of proteome research.

[24]  B. Strom,et al.  Antidepressant use and colorectal cancer risk , 2009, Pharmacoepidemiology and drug safety.

[25]  H. Wakabayashi,et al.  Increased Levels of ɛ and γ Isoforms of 14-3-3 Proteins in Cerebrospinal Fluid in Patients with Creutzfeldt-Jakob Disease , 1999, Clinical Diagnostic Laboratory Immunology.

[26]  G. Meijer,et al.  Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications. , 2013, Clinical biochemistry.

[27]  Jian-Ting Zhang,et al.  14-3-3sigma, the double-edged sword of human cancers. , 2009, American journal of translational research.

[28]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  L. Boros,et al.  Fructose induces transketolase flux to promote pancreatic cancer growth. , 2010, Cancer research.

[30]  Wenwen Wu,et al.  Protein Pattern Difference in the Colon Cancer Cell Lines Examined by Two-Dimensional Differential In-Gel Electrophoresis and Mass Spectrometry , 2006, Surgery Today.

[31]  Juan Liu,et al.  The regulation of cellular metabolism by tumor suppressor p53 , 2013, Cell & Bioscience.

[32]  Claudio R. Santos,et al.  Lipid metabolism in cancer , 2012, The FEBS journal.

[33]  Liang Zhao,et al.  Nuclear localization of 14‐3‐3epsilon inversely correlates with poor long‐term survival of patients with colorectal cancer , 2012, Journal of surgical oncology.

[34]  W. Muller,et al.  A novel role for 14-3-3sigma in regulating epithelial cell polarity. , 2010, Genes & development.

[35]  C. Tei,et al.  Clinical significance of serum neuron‐specific enolase in patients with adult T‐cell leukemia , 2002, American journal of hematology.

[36]  Jan Maarten van Dijl,et al.  A proteomic view on genome-based signal peptide predictions. , 2001, Genome research.

[37]  I. Craig,et al.  Localisation of neurone-specific enolase (ENO2) to 12p13. , 1990, Cytogenetics and Cell Genetics.

[38]  Hanlin L. Wang,et al.  Colorectal carcinoma: Pathologic aspects. , 2012, Journal of gastrointestinal oncology.

[39]  M. Zarrindast,et al.  Study of 5HT3 and HT4 receptor expression in HT29 cell line and human colon adenocarcinoma tissues. , 2010, Archives of Iranian medicine.

[40]  T. Heusner,et al.  Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancer. , 2010, Anticancer research.

[41]  N. Istfan,et al.  Fructose consumption and cancer: is there a connection? , 2012, Current opinion in endocrinology, diabetes, and obesity.

[42]  Martina Tinzl,et al.  Expression and localization of serotonin receptors in human breast cancer. , 2013, Anticancer research.

[43]  F. Lembeck,et al.  5-Hydroxytryptamine in a Carcinoid Tumour , 1953, Nature.

[44]  P. Hardt,et al.  Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. , 2003, Anticancer research.

[45]  D. Karnak,et al.  Neuron-Specific Enolase and Lung Cancer , 2005, American journal of clinical oncology.

[46]  B. Turk,et al.  AMPK phosphorylation of raptor mediates a metabolic checkpoint. , 2008, Molecular cell.

[47]  Shung-Haur Yang,et al.  Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis , 2012, International Journal of Colorectal Disease.

[48]  D. Morrison,et al.  The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. , 2009, Trends in cell biology.

[49]  Jaw-Yuan Wang,et al.  Significance of the glycolytic pathway and glycolysis related-genes in tumorigenesis of human colorectal cancers. , 2008, Oncology reports.

[50]  Jing Fang,et al.  Pyruvate kinase type M2 is upregulated in colorectal cancer and promotes proliferation and migration of colon cancer cells , 2012, IUBMB life.

[51]  C. Hew,et al.  Proteomic Analysis of Colorectal Cancer Reveals Alterations in Metabolic Pathways , 2006, Molecular & Cellular Proteomics.

[52]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[53]  E. Diamandis,et al.  Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines* , 2009, Molecular & Cellular Proteomics.

[54]  Lining Guo,et al.  Untargeted Metabolomic Profiling as an Evaluative Tool of Fenofibrate-Induced Toxicology in Fischer 344 Male Rats , 2009, Toxicologic pathology.

[55]  N. Anderson,et al.  The Human Plasma Proteome: History, Character, and Diagnostic Prospects , 2003, Molecular & Cellular Proteomics.

[56]  E Altobelli,et al.  Colorectal cancer prevention in Europe: burden of disease and status of screening programs. , 2014, Preventive medicine.

[57]  G. Tzivion,et al.  14-3-3 proteins as potential oncogenes. , 2006, Seminars in cancer biology.

[58]  E. Petricoin,et al.  Analysis of urinary human growth hormone (hGH) using hydrogel nanoparticles and isoform differential immunoassays after short recombinant hGH treatment: preliminary results. , 2013, Journal of pharmaceutical and biomedical analysis.

[59]  H. Grimm,et al.  Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. , 2002, Anticancer research.

[60]  M. S. Lee,et al.  Determination of plasma serotonin and 5-hydroxyindoleacetic acid in healthy subjects and cancer patients. , 2000, Clinical chemistry.

[61]  E. Eigenbrodt,et al.  Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. , 1997, Anticancer research.

[62]  L. Boros,et al.  Direct Spectrophotometric Determination of Serum Fructose in Pancreatic Cancer Patients , 2009, Pancreas.

[63]  D. Samid,et al.  Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine , 1995, Journal of clinical pharmacology.

[64]  Giuseppe Caruso,et al.  Comparison of three different enrichment strategies for serum low molecular weight protein identification using shotgun proteomics approach. , 2012, Analytica chimica acta.

[65]  D. Morrison,et al.  Unlocking the code of 14-3-3 , 2004, Journal of Cell Science.

[66]  P. Wild,et al.  Serotonin promotes tumor growth in human hepatocellular cancer , 2010, Hepatology.

[67]  Congjian Xu,et al.  LC-MS/MS analysis of ovarian cancer metastasis-related proteins using a nude mouse model: 14-3-3 zeta as a candidate biomarker. , 2010, Journal of proteome research.

[68]  K. Koss,et al.  Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. , 2012, World journal of gastroenterology.

[69]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[70]  A. Aitken,et al.  Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. , 2007, The Journal of rheumatology.

[71]  Y. Kloog,et al.  Metabolism addiction in pancreatic cancer , 2014, Cell Death and Disease.

[72]  M. Peinado,et al.  Role of caveolin 1, E-cadherin, Enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells. , 2008, BMC medical genomics.

[73]  D. Tang,et al.  PKM2, a Central Point of Regulation in Cancer Metabolism , 2013, International journal of cell biology.

[74]  C. Clarke,et al.  A novel panel of protein biomarkers for predicting response to thalidomide‐based therapy in newly diagnosed multiple myeloma patients , 2011, Proteomics.

[75]  Shu Zheng,et al.  Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening. , 2012, World journal of gastrointestinal oncology.

[76]  E. Boschetti,et al.  Hexapeptide combinatorial ligand libraries: the march for the detection of the low-abundance proteome continues. , 2008, BioTechniques.

[77]  H. Hermeking.  The 14-3-3 cancer connection , 2003, Nature Reviews Cancer.

[78]  C. McLean,et al.  Creutzfeldt-Jakob disease: diagnostic utility of 14–3–3 protein immunodetection in cerebrospinal fluid , 2000, Journal of Clinical Neuroscience.